Talazoparib Plus Low-Dose Temozolomide Bests Historical Controls in R/R ES-SCLC
August 08, 2022

Data from the phase 2 UCLA/TRIO-US L-07 trial presented at 2022 WCLC revealed that efficacy with talazoparib plus temozolomide improves upon historical controls in patients with extensive-stage small cell lung cancer.

ES-SCLC Responds to Temozolomide Plus Nivolumab Following Prior Chemotherapy
August 08, 2022

Response rates with temozolomide plus nivolumab in extensive-stage small cell lung cancer show promise.

Leading Resistance Mechanism to Osimertinib Identified as EGFR C797X, According to Real-World Analysis
August 08, 2022

EGFR C797X mutations identified as leading cause of acquired resistance to osimertinib, according to real-world data from 2022 WCLC.

Half of Patients With Pretreated EGFR+ NSCLC Respond to Regimen Containing Amivantamab and Lazertinib
August 08, 2022

According to data from the phase 1 CHRYSALIS-2 trial that were presented at 2022 WCLC, a combination containing amivantamab, lazertinib, and chemotherapy was effective in patients with pretreated non–small cell lung cancer harboring EGFR mutations.

Addition of Tremelimumab to Durvalumab Regimen Induces Greater Survival Outcomes in PD-L1–Negative NSCLC
August 08, 2022

The phase 3 POSEIDON trial showed superior overall survival in patients with PD-L1–negative metastatic non–small cell lung cancer who were given durvalumab and chemotherapy plus tremelimumab.

Evidence of Antitumor Effect With GDC-6036 Monotherapy in KRAS G12C+ NSCLC Revealed at 2022 WCLC
August 08, 2022

The novel KRAS G12C inhibitor GDC-6036 induced a high response rate in patients with previously treated KRAS G12C mutation–positive non–small cell lung cancer.

Neoadjuvant Nivolumab/Chemo Demonstrates Superiority Vs Chemo Alone in Resectable Stage IIIA/B NSCLC
August 08, 2022

Data from the phase 2 NADIM II trial appear to reinforce the superiority of nivolumab and chemotherapy vs chemotherapy alone after the regimen significantly improved overall survival progression-free survival, and pathologic complete response in patients with stage IIIA/B non–small cell lung cancer, according to investigators.

IMpower010 Trial Highlights Trend Towards OS Benefit With Atezolizumab in Resected NSCLC
August 08, 2022

Data indicate that atezolizumab may achieve overall survival benefit compared with best supportive care in resected non–small cell lung cancer.

CodeBreak100/101 Data Show Promise of Safety Lead-in With Sotorasib Plus Pembrolizumab for KRAS G12C+ NSCLC
August 07, 2022

Following data presented from the phase 1/2 CodeBreak 100 and CodeBreak 101 trials, a regimen consisting of sotorasib with a safety lead-in followed by concurrent pembrolizumab will be further explored in patients with KRAS G12C–mutant non–small cell lung cancer.

Phase 2 Study Results Suggest Similar Efficacy, Safety of Sintilimab Vs Pembrolizumab in Advanced NSCLC
August 07, 2022

Patients with treatment-naïve metastatic non–small cell lung cancer who received either sintilimab or pembrolizumab monotherapy, or either agent combined with chemotherapy, experienced comparable outcomes.